At a glance
ClinicalIndex Comparison Record- ✓Prior chemotherapy for breast cancer (optional inclusion criterion)
- ✓Greater than 25 cm breast separation on planning CT
- ✓Non-Caucasian race (optional inclusion criterion)
- ✓Age 50 years or younger
- ✕Male sex
- ✕Pregnant or nursing women
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study of Hypofractionated Simultaneous Integrated Boost Radiotherapy in Stage 0, I and III Breast Cancer Patients
In Brief
A clinical study evaluating Hypofractionated Simultaneous Integrated Boost Radiotherapy for Cancer, Breast and Inflammation. Completed, enrolled 74 participants across 1 site.
Detailed Summary
As the number of breast cancer (BrCA) survivors has markedly increased, clinicians are now seeking to reduce treatment-related toxicities and inconveniences of treatment, namely the traditional 6 weeks of daily radiation treatment (XRT). Skin thickening, fibrosis, and edema are some of the most common acute and potentially long-term debilitating toxicities of BrCA XRT. The purpose of this study is to learn if three weeks of daily radiation treatment (RT) to the breast is safe in breast cancer patients who are usually prescribed 6 weeks of daily radiation after breast surgery (e.g. lumpectomy or mastectomy) as standard of care.
Study Details
Timeline
Interventions
Participants will receive radiotherapy treatments to the whole breast or chest wall to a dose of 2.66 Gy per day x 15 fractions simultaneously with a boost treatment. The boost treatment will be given on the same days as the whole breast treatment. The lumpectomy cavity + scar (in lumpectomy patients) or chest wall scar (mastectomy patients) will receive 0.54 Gy per day x 15 fractions.